Literature DB >> 23339184

Microenvironmental regulation of BRCA1 gene expression by c-Jun and Fra2 in premalignant human ovarian surface epithelial cells.

Lixin Zhou1, Marcia Graves, Gwen MacDonald, Jane Cipollone, Christopher R Mueller, Calvin D Roskelley.   

Abstract

Reduced BRCA1 gene expression is common in the sporadic form of ovarian carcinoma. The spread of this highly lethal cancer often begins when tumor cell clusters are shed into the fluid of the abdominopelvic cavity such that they can float freely before seeding distant sites on the peritoneal walls and organs. Thus, the microenvironment that tumor cells find themselves in changes dramatically during these early shedding and floating stages of transperitoneal metastasis. To mimic this microenvironmental change in vitro, we released premalignant human ovarian surface epithelial cells from the substratum and forced them to cluster in suspension. Under these conditions, steady state levels of BRCA1 mRNA and protein fell significantly and the transcriptional activation state of the BRCA1 promoter was suppressed. Analysis of the promoter indicated that the previously identified "CRE" element located within the "positive regulatory region" (PRR) contributed to this suppression. More specifically, we show that the suppression was mediated, at least in part, by a suspension culture-driven decrease in the levels of two members of the AP1 transcription factor complex, c-Jun and Fra2, that bind to the CRE element. Therefore, a microenvironmental change that is manifested during the initial stages of ovarian carcinoma dissemination may, potentially, help suppress BRCA1 expression in sporadic tumors and thus promote their progression.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23339184     DOI: 10.1158/1541-7786.MCR-12-0395

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  8 in total

Review 1.  Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis.

Authors:  Sabita N Saldanha; Trygve O Tollefsbol
Journal:  J Cell Physiol       Date:  2014-04       Impact factor: 6.384

2.  FOSL2 positively regulates TGF-β1 signalling in non-small cell lung cancer.

Authors:  Junfeng Wang; Dawei Sun; Yanbo Wang; Fenghai Ren; Sainan Pang; Dandan Wang; Shidong Xu
Journal:  PLoS One       Date:  2014-11-06       Impact factor: 3.240

3.  miR-597 inhibits breast cancer cell proliferation, migration and invasion through FOSL2.

Authors:  Jiangtu He; Jieying Mai; Yan Li; Linyi Chen; Hui Xu; Xiaofei Zhu; Qiuhui Pan
Journal:  Oncol Rep       Date:  2017-04-05       Impact factor: 3.906

4.  Hyaluronan Metabolism is Associated with DNA Repair Genes in Breast and Colorectal Cancer. Screening of Potential Progression Markers Using qPCR.

Authors:  Ina Sevic; Fiorella Mercedes Spinelli; Daiana Lujan Vitale; Antonella Icardi; Lucia Romano; Alejandra Brandone; Paula Giannoni; Carolina Cristina; Marcela Fabiana Bolontrade; Laura Alaniz
Journal:  Biomedicines       Date:  2020-06-29

5.  Selective participation of c-Jun with Fra-2/c-Fos promotes aggressive tumor phenotypes and poor prognosis in tongue cancer.

Authors:  Shilpi Gupta; Prabhat Kumar; Harsimrut Kaur; Nishi Sharma; Daman Saluja; Alok C Bharti; Bhudev C Das
Journal:  Sci Rep       Date:  2015-11-19       Impact factor: 4.379

6.  FAM49B, a novel regulator of mitochondrial function and integrity that suppresses tumor metastasis.

Authors:  M S Chattaragada; C Riganti; M Sassoe; M Principe; M M Santamorena; C Roux; C Curcio; A Evangelista; P Allavena; R Salvia; B Rusev; A Scarpa; P Cappello; F Novelli
Journal:  Oncogene       Date:  2017-10-23       Impact factor: 9.867

7.  Role of linc00174/miR-138-5p (miR-150-5p)/FOSL2 Feedback Loop on Regulating the Blood-Tumor Barrier Permeability.

Authors:  Jizhe Guo; Shuyuan Shen; Xiaobai Liu; Xuelei Ruan; Jian Zheng; Yunhui Liu; Libo Liu; Jun Ma; Teng Ma; Lianqi Shao; Di Wang; Chunqing Yang; Yixue Xue
Journal:  Mol Ther Nucleic Acids       Date:  2019-11-09       Impact factor: 8.886

8.  Copy Number Variations of CEP63, FOSL2 and PAQR6 Serve as Novel Signatures for the Prognosis of Bladder Cancer.

Authors:  Zhao Cai; Huang Chen; Jingqiao Bai; Yang Zheng; Jianhui Ma; Xiongwei Cai; Yu Liu; Kaitai Zhang; Jianzhong Shou; Yanning Gao
Journal:  Front Oncol       Date:  2021-05-10       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.